FindTrial
Sign In

See below

See below

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2018-004438-14-SE
Enrollment
402
Registered
2019-05-09
Start date
2019-06-24
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

See below

Interventions

Trade Name: Avastin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-75-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration

Sponsors

Västra Götalandsregionen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: See below Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 402 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: See below

Design outcomes

Primary

MeasureTime frame
Main Objective: See below;Secondary Objective: See below;Primary end point(s): See below;Timepoint(s) of evaluation of this end point: See below—

Secondary

MeasureTime frame
Secondary end point(s): See below;Timepoint(s) of evaluation of this end point: See below—

Countries

Sweden

Contacts

Public ContactMadeleine Zetterberg

Västra Götalandregionen

madeleine.zetterberg@vgregion.se+46313433255

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026